Sangui Biotech International, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023
February 14, 2024
Share
Sangui Biotech International, Inc. reported earnings results for the second quarter and six months ended December 31, 2023. For the second quarter, the company reported revenue was USD 0.034153 million compared to USD 0.010627 million a year ago. Net loss was USD 0.039758 million compared to USD 0.102289 million a year ago.
For the six months, revenue was USD 0.054876 million compared to USD 0.051656 million a year ago. Net loss was USD 0.031659 million compared to USD 0.079057 million a year ago.
Sangui Biotech International, Inc. focuses on the development of pharmaceutical, medical and cosmetic products. The Company develops its products through its German subsidiary, SanguiBioTech AG (Sangui GmbH). It is engaged in seeking to market and selling its products through partnerships with industry partners across the world. It focuses on the development of oxygen carriers capable of providing oxygen transport in humans in the event of acute and/or chronic lack of oxygen due to arterial occlusion, anemia or blood loss whether due to surgery, trauma, or other causes. It focuses its development and commercialization efforts on such artificial oxygen carriers by reproducing and synthesizing polymers out of native hemoglobin of defined molecular sizes. It offers external applications of oxygen transporters in the medical and cosmetic fields in the form of sprays for the healing of chronic wounds and of gels and emulsions for the regeneration of the skin.
SANGUI BIOTECH INTERNATIONAL, INC. 
